CL2017001467A1 - Compuestos de dihidropirimidin - 2 - ona y sus usos médicos - Google Patents
Compuestos de dihidropirimidin - 2 - ona y sus usos médicosInfo
- Publication number
- CL2017001467A1 CL2017001467A1 CL2017001467A CL2017001467A CL2017001467A1 CL 2017001467 A1 CL2017001467 A1 CL 2017001467A1 CL 2017001467 A CL2017001467 A CL 2017001467A CL 2017001467 A CL2017001467 A CL 2017001467A CL 2017001467 A1 CL2017001467 A1 CL 2017001467A1
- Authority
- CL
- Chile
- Prior art keywords
- dihydropyrimidin
- compounds
- medical uses
- symbol
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C265/00—Derivatives of isocyanic acid
- C07C265/02—Derivatives of isocyanic acid having isocyanate groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/12—Organo silicon halides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cephalosporin Compounds (AREA)
Abstract
<p>UN COMPUESTO DE FORMULA [I] O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES, DONDE CADA SÍMBOLO SE DEFINE COMO EN LA MEMORIA DESCRIPTIVA.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014251771 | 2014-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001467A1 true CL2017001467A1 (es) | 2018-01-05 |
Family
ID=56107519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001467A CL2017001467A1 (es) | 2014-12-12 | 2017-06-08 | Compuestos de dihidropirimidin - 2 - ona y sus usos médicos |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US10196363B2 (es) |
| EP (2) | EP3744713A1 (es) |
| JP (4) | JP6757565B2 (es) |
| KR (1) | KR102551018B1 (es) |
| CN (1) | CN107001286B (es) |
| AR (1) | AR102972A1 (es) |
| AU (1) | AU2015362394C1 (es) |
| BR (1) | BR112017010471B1 (es) |
| CA (1) | CA2965804C (es) |
| CL (1) | CL2017001467A1 (es) |
| CO (1) | CO2017005732A2 (es) |
| CY (1) | CY1122971T1 (es) |
| DK (1) | DK3231793T3 (es) |
| ES (1) | ES2787700T3 (es) |
| HR (1) | HRP20200584T1 (es) |
| HU (1) | HUE048503T2 (es) |
| IL (2) | IL251940B (es) |
| LT (1) | LT3231793T (es) |
| ME (1) | ME03760B (es) |
| MX (1) | MX371128B (es) |
| MY (1) | MY193671A (es) |
| PE (1) | PE20171119A1 (es) |
| PH (1) | PH12017501071B1 (es) |
| PL (1) | PL3231793T3 (es) |
| PT (1) | PT3231793T (es) |
| RS (1) | RS60352B1 (es) |
| RU (1) | RU2770061C2 (es) |
| SA (1) | SA517381678B1 (es) |
| SG (2) | SG11201703885TA (es) |
| SI (1) | SI3231793T1 (es) |
| SM (1) | SMT202000215T1 (es) |
| TW (2) | TWI690515B (es) |
| WO (1) | WO2016093342A1 (es) |
| ZA (1) | ZA201703976B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015362394C1 (en) * | 2014-12-12 | 2021-01-28 | Japan Tobacco Inc. | Dihydropyrimidine-2-one compounds and medicinal uses thereof |
| CN106496008A (zh) * | 2016-10-20 | 2017-03-15 | 上海毕得医药科技有限公司 | 一种合成4‑(4‑氯苯基)环己酮的方法 |
| KR20200126973A (ko) * | 2018-02-28 | 2020-11-09 | 니뽄 다바코 산교 가부시키가이샤 | 4-메틸디히드로피리미디논 화합물 및 그의 의약 용도 |
| CN111741948B (zh) * | 2018-02-28 | 2023-11-10 | 日本烟草产业株式会社 | 饱和环稠合的二氢嘧啶酮或二氢三嗪酮化合物及其药物用途 |
| CN110294762B (zh) * | 2019-06-14 | 2020-12-15 | 深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） | 检测米酵菌酸中毒的人工抗原及应用 |
| WO2021149786A1 (en) | 2020-01-24 | 2021-07-29 | Japan Tobacco Inc. | Methods of treating cancer using dihydropyrimidin-2-one compounds |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
| CN117430562A (zh) * | 2023-09-26 | 2024-01-23 | 中山大学 | 一种4-甲基-2-氧代-3,6-二氢嘧啶类化合物及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485107A (en) * | 1982-11-01 | 1984-11-27 | Janssen Pharmaceutica N.V. | [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones |
| EP1962855B1 (en) * | 2005-12-22 | 2013-08-21 | Hydra Biosciences, Inc. | Trpa1 inhibitors for treating pain |
| DE102006031314A1 (de) * | 2006-07-01 | 2008-01-03 | Bayer Healthcare Aktiengesellschaft | Verwendung von 1,4-Diaryl-dihydropyrimidin-2-on-Derivaten zur Behandlung der pulmonalen arteriellen Hyptertonie |
| ES2366766T3 (es) | 2007-08-09 | 2011-10-25 | F. Hoffmann-La Roche Ag | Derivados de benzoílpiperidina como modulares duales de los receptores 5-ht2a y d3. |
| US20110201634A1 (en) * | 2008-06-13 | 2011-08-18 | Delhi University | Dihydropyridimidinone compounds for the treatment of cardiovascular diseases and process for preparing the same |
| WO2012147916A1 (ja) * | 2011-04-28 | 2012-11-01 | 日本たばこ産業株式会社 | アミド化合物およびその医薬用途 |
| EP2682389A1 (en) | 2012-07-02 | 2014-01-08 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Dihydropyrimidin-2(1H)-ones and dihydropyrimidin-2(1H)-thiones as inhibitors of sodium iodide symporter |
| WO2014062938A1 (en) | 2012-10-19 | 2014-04-24 | Bristol-Myers Squibb Company | Rory modulators |
| US20160137639A1 (en) | 2012-10-26 | 2016-05-19 | Japan Tobacco Inc. | Triazole-isoxazole compound and medical use thereof |
| CN103113308B (zh) * | 2013-01-25 | 2014-11-19 | 浙江大学 | 一种制备二氢嘧啶酮衍生物的方法 |
| UA120108C2 (uk) | 2014-12-12 | 2019-10-10 | Мерк Патент Гмбх | Комбінація похідної 6-оксо-1,6-дигідропіридазину, що має протиракову активність, з інгібітором рефр |
| AU2015362394C1 (en) * | 2014-12-12 | 2021-01-28 | Japan Tobacco Inc. | Dihydropyrimidine-2-one compounds and medicinal uses thereof |
| CA2970500C (en) | 2014-12-12 | 2023-08-29 | Acetylon Pharmaceuticals, Inc. | Piperidine derivatives as hdac1/2 inhibitors |
| MA41148A (fr) | 2014-12-12 | 2017-10-17 | H Lundbeck As | Procédé de fabrication d'idalopirdine |
| TW201630881A (zh) | 2014-12-12 | 2016-09-01 | Ｈ 朗德貝克公司 | 用於生產艾達魯吡啶之方法 |
-
2015
- 2015-12-11 AU AU2015362394A patent/AU2015362394C1/en not_active Ceased
- 2015-12-11 TW TW104141671A patent/TWI690515B/zh active
- 2015-12-11 RS RS20200583A patent/RS60352B1/sr unknown
- 2015-12-11 HU HUE15866802A patent/HUE048503T2/hu unknown
- 2015-12-11 PH PH1/2017/501071A patent/PH12017501071B1/en unknown
- 2015-12-11 US US14/966,120 patent/US10196363B2/en active Active
- 2015-12-11 JP JP2015241742A patent/JP6757565B2/ja active Active
- 2015-12-11 SM SM20200215T patent/SMT202000215T1/it unknown
- 2015-12-11 CA CA2965804A patent/CA2965804C/en active Active
- 2015-12-11 MY MYPI2017702091A patent/MY193671A/en unknown
- 2015-12-11 WO PCT/JP2015/084791 patent/WO2016093342A1/ja not_active Ceased
- 2015-12-11 ES ES15866802T patent/ES2787700T3/es active Active
- 2015-12-11 LT LTEP15866802.0T patent/LT3231793T/lt unknown
- 2015-12-11 PL PL15866802T patent/PL3231793T3/pl unknown
- 2015-12-11 CN CN201580067185.0A patent/CN107001286B/zh active Active
- 2015-12-11 SG SG11201703885TA patent/SG11201703885TA/en unknown
- 2015-12-11 KR KR1020177018832A patent/KR102551018B1/ko active Active
- 2015-12-11 HR HRP20200584TT patent/HRP20200584T1/hr unknown
- 2015-12-11 DK DK15866802.0T patent/DK3231793T3/da active
- 2015-12-11 PE PE2017000974A patent/PE20171119A1/es unknown
- 2015-12-11 RU RU2017124423A patent/RU2770061C2/ru not_active Application Discontinuation
- 2015-12-11 EP EP20161939.2A patent/EP3744713A1/en active Pending
- 2015-12-11 EP EP15866802.0A patent/EP3231793B1/en active Active
- 2015-12-11 ME MEP-2020-61A patent/ME03760B/me unknown
- 2015-12-11 TW TW108140988A patent/TWI739206B/zh not_active IP Right Cessation
- 2015-12-11 AR ARP150104039A patent/AR102972A1/es active IP Right Grant
- 2015-12-11 SI SI201531175T patent/SI3231793T1/sl unknown
- 2015-12-11 BR BR112017010471-7A patent/BR112017010471B1/pt active IP Right Grant
- 2015-12-11 PT PT158668020T patent/PT3231793T/pt unknown
- 2015-12-11 MX MX2017007577A patent/MX371128B/es active IP Right Grant
- 2015-12-11 SG SG10202010291VA patent/SG10202010291VA/en unknown
-
2017
- 2017-04-26 IL IL251940A patent/IL251940B/en active IP Right Grant
- 2017-06-07 SA SA517381678A patent/SA517381678B1/ar unknown
- 2017-06-08 CL CL2017001467A patent/CL2017001467A1/es unknown
- 2017-06-09 CO CONC2017/0005732A patent/CO2017005732A2/es unknown
- 2017-06-09 ZA ZA2017/03976A patent/ZA201703976B/en unknown
-
2018
- 2018-12-20 US US16/228,448 patent/US20190359575A1/en not_active Abandoned
-
2020
- 2020-05-20 CY CY20201100462T patent/CY1122971T1/el unknown
- 2020-06-16 US US16/902,935 patent/US20210130300A1/en not_active Abandoned
- 2020-08-31 JP JP2020145707A patent/JP2020200339A/ja active Pending
-
2021
- 2021-05-20 IL IL283335A patent/IL283335B/en unknown
-
2022
- 2022-05-31 JP JP2022088388A patent/JP2022116239A/ja active Pending
- 2022-12-20 US US18/085,466 patent/US20230373932A1/en not_active Abandoned
-
2024
- 2024-07-08 JP JP2024109343A patent/JP2024133646A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261621A (en) | Genome edited immune effector cells | |
| CO2017005732A2 (es) | Compuestos de dihidropirimidin-2-ona y sus usos médicos | |
| CO2017005790A2 (es) | Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas | |
| MX377396B (es) | Compuestos de azapiridona y usos de los mismos. | |
| CR20150509A (es) | Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina | |
| MX385585B (es) | Anticuerpos anti-c10orf54 y usos de los mismos. | |
| MX381417B (es) | Inhibidores de glucosidasa. | |
| CR20160602A (es) | Compuestos de [1,2,4] Triazol sustituido | |
| MX2016016870A (es) | Compuestos heterociclicos y su uso como inhibidores de receptor huerfano relacionado con retinoide (ror) gamma-t. | |
| MX2015009479A (es) | Compuestos y metodos para tratar infecciones bacterianas. | |
| CR20160044S (es) | Dispensador de jabon | |
| EA201790627A1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
| MX2021005052A (es) | Oxiesteroles y métodos de uso de los mismos. | |
| MX2017011194A (es) | Anticuerpos, usos y métodos. | |
| PT3218365T (pt) | 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetra-hidropiridinas como inibidores da bace1 | |
| CR20170008A (es) | Compuestos de [1,2,4] triazol e imidazol sustituidos | |
| BR112016027691A2 (pt) | Composto de tetra-hidropiridopirimidina e seus usos | |
| MX2017002312A (es) | Compuestos heterobiciclicos y su uso para el tratamiento de tuberculosis. | |
| CL2014003123A1 (es) | 5-amino [1,4], tiazinas como inhibidores de bace1; uso del compuesto contra la enfermedad de alzheimer. | |
| ECSP16096831A (es) | Derivados de naftiridinadiona | |
| MX2020003816A (es) | Compuesto de heteroarilo con contenido de nitrogeno, y su uso farmaceutico. | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| EA201790526A1 (ru) | Фармацевтические комбинации ситаглиптина | |
| RU2014115406A (ru) | Применение 8-(трифторметил)бензо[f][1,2,3,4,5]пентатиепин-6-амина в качестве антидепрессанта | |
| DOP2017000016A (es) | Nueva sal de disoproxilo de tenofovir |